• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    M

    Mayo Clinic Health System

    EST. 1992
    1,227论文总数
    1.2万引用总数

    Mayo Clinic partially owns and operates Mayo Clinic Health System. Founded in 1992, Mayo Clinic Health System is as a network of community-based medical services. In 2021, it consisted of more than 40 hospitals and clinics in Minnesota, Iowa, and Wisconsin. The President of Mayo Clinic Health System, Prathibha Varkey, M.B.B.S. (since 2021), is a board member of the Mayo Clinic Board of Directors.

    论文量&引用量时间轴

    机构学者

    论文(1229)

    年份
    起
    –
    止
    排序
    1Beyond Biological Risk: Socioeconomic Vulnerability and Adverse Pediatric Kidney Transplant Outcomes
    Sarah Kizilbash, Chung-II Wi,Sandra Amaral, Madison Beenken, David Watson, Warren McKinney, Young Juhn

    Adverse social determinants are known contributors to poorer long-term allograft outcomes. Yet optimal measures of social determinants are lacking. We sought to evaluate the association between socioeconomic status (SES) and graft loss in children using several different metrics of social determinants of health (SDOH). Our study included 137 pediatric kidney transplant recipients (< 18 years at kidney failure onset) transplanted between 2010 and 2020. The association between SES measures (individual- and area-level) and graft survival was examined using Cox regression models. Measures were dichotomized: HOUSES Index [low SES(Q1) vs. high (Q2–Q4)], Area Deprivation Index (ADI) [high deprivation (76–100 percentile) vs. low (1–75 percentile)], and Childhood Opportunity Index (COI) [low opportunity (1s–25 percentile) vs. high (26–100)]. All models were adjusted for transplant age, sex, donor type, pretransplant dialysis, insurance, kidney failure cause, and body mass index z-score. After adjusting for covariates, we observed a significantly increased risk of graft loss in HOUSES Q1 vs. Q2–4 recipients (adjusted hazard ratio [aHR]: 3.25; 95

    2026Pediatric Nephrology(2026)引用:33
    引用
    AI阅读
    加入学术空间
    2Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
    Kristin A Higgins,Chen Hu,Helen J Ross, Salma K Jabbour, David E Kozono, Taofeek K Owonikoko, Timothy A Ritter,Terence M Williams,James Welsh, Jeffry P Simko, B Movsas, Canhua Xiao,

    PURPOSE:NRG Oncology/Alliance LU005 (ClinicalTrials.gov identifier: NCT03811002) tested the addition of atezolizumab to concurrent chemoradiation (CRT) in this open-label, phase III international trial. METHODS:Patients with limited-stage small cell lung cancer (LS-SCLC), stage Tx-IV, N0-3, and M0 with Eastern Cooperative Group performance status (PS) 0-2 received one cycle of chemotherapy (platinum/etoposide) before study registration and were randomly assigned to CRT alone versus CRT plus concurrent and adjuvant atezolizumab, 1,200 mg once daily, every 3 weeks until investigator-assessed progression or intolerable side effects for a maximum of 17 cycles. Patients were stratified by choice of chemotherapy (cisplatin v carboplatin), radiation fractionation schedule (66 Gy once daily v 45 Gy twice daily), sex, and PS (0/1 v 2). The primary end point was overall survival (OS). Secondary end points included investigator-assessed progression-free survival (PFS), objective response rate, local control, and distant-metastasis-free survival (DMFS). RESULTS:patients were randomly assigned from May 2019 to December 2023. The median OS was 36.1 months (95% CI, 28.1 to 42.5) for the CRT-alone arm and 31.1 months (95% CI, 28.5 to 44.7) for the CRT + atezolizumab arm, respectively (hazard ratio [HR], 1.03 [95% CI, 0.80 to 1.32]). The median PFS was 11.4 months (95% CI, 10.3 to 13.2) for the CRT-alone arm and 12.1 months (95% CI, 10.9 to 15.2) for the CRT + atezolizumab arm, respectively (HR, 0.98 [95% CI, 0.79 to 1.22]). The median DMFS was 13.0 months (95% CI, 11.3 to 18.2) for the CRT-alone arm and 16.8 months (95% CI, 12.1 to 21.6) for the CRT + atezolizumab arm (HR, 0.96 [95% CI, 0.76 to 1.21]). No unexpected safety signals with concurrent atezolizumab were observed. CONCLUSION:Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.

    2026Journal of clinical oncology official journal of the American Society of Clinical Oncology(2026)引用:7
    引用
    AI阅读
    加入学术空间
    3Impact of Broadband Availability and Digital Literacy on Video Telehealth Use among Cancer Patients
    Joshua C. Pritchett,Pravesh Sharma,Ming Huang, Ruchita Dholakia,Tabetha A. Brockman,James P. Moriarty, Celia C. Kamath, Hannah Ahn,Paul A. Decker,Ruoxiang Jiang, Jonathan Ticku,Nandita Khera,

    Video telehealth visits (VTV) have emerged as a critical tool for oncology care delivery, with potential to address longstanding access disparities. We examined the association between broadband internet availability, individual digital literacy factors, and VTV utilization among patients with cancer. In a retrospective cohort of 13,897 patients across a multi-site practice, VTV utilization was significantly lower in areas with ≤1 internet service provider (ISP) offering download speeds ≥25 Mbps (p = 0.0009). Validation in a regional cohort (n = 6665) confirmed lower VTV utilization in low-broadband areas. Among 1134 surveyed patients, higher digital literacy was the strongest predictor of VTV use (OR 2.5; p < 0.001), even where broadband was limited. This study demonstrates that while both broadband availability and digital literacy independently influence VTV utilization, individual digital skills can partially offset structural limitations, underscoring the need for concurrent investment in broadband infrastructure and targeted digital literacy initiatives to advance access to care.

    2026npj Digital Medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Comparative Clinical Characteristics of ICU and Non-ICU Hospitalized Patients with Human Anaplasmosis
    Igor Dumic, Marie Schultz, Christopher Benny, Jennifer Rich, Aryan Shiari

    Background:Human granulocytic anaplasmosis (HGA) can cause severe illness requiring intensive care, but factors associated with critical illness among hospitalized patients are incompletely described. Method:We performed a retrospective multicenter cohort study of adults hospitalized with PCR-confirmed HGA at Mayo Clinic Rochester and affiliated Mayo Clinic Health System sites in Minnesota and Wisconsin from 2014 through 2024. Patients who required ICU-level care were compared with those managed on general medical wards using exploratory univariate analyses (Fisher exact and Kruskal-Wallis tests). Results:Among 101 hospitalized patients, 12 (12%) required ICU-level care. Symptoms documented at hospital presentation/admission were more frequent in ICU patients, including vomiting (64% vs 30%) and abdominal pain (55% vs 26%). On admission, ICU patients had lower sodium (mean 128.8 vs 132.3 mmol/L) and higher total bilirubin (mean 1.3 vs 0.8 mg/dL). Platelet nadir during hospitalization was lower in ICU patients (mean 54.8 × 109/L vs 84.1 × 109/L). Peak ferritin, measured in a subset, was markedly higher in ICU patients (median 21 666 vs 961 µg/L). The composite endpoint of HGA-related complications or serious treatment-related adverse events occurred more often in ICU patients (75% vs 17%); one death occurred in the ICU group. Conclusions:In hospitalized adults with HGA, ICU-level care was associated with gastrointestinal symptoms at presentation/admission, admission hyponatremia and hyperbilirubinemia, lower platelet nadir, and marked hyperferritinemia when measured. Because these findings were derived from univariate group-level comparisons with substantial overlap between groups, they should be viewed as hypothesis-generating rather than individually predictive or sufficient as stand-alone triage criteria.

    2026Open forum infectious diseases(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Immunoediting Restricts Clonal Neoantigens in Primary, Treatment-Naive Human Tumors.
    Elizabeth S Borden,David Castellano, Emily A Kantzos,Alysia Hughes, Zachary Leibovit-Reiben,Alyssa Stockard,Anirudh Choudhary,Tao Ma,Xing Li,Aaron R Mangold,Ryan N Gutenkunst,Bonnie J LaFleur,

    T cell targeting of cancer cells alters the tumor antigen landscape in preclinical models. Here, we examined the impact of immunoediting on the antigenic landscape of primary, treatment-naive human tumors. Cutaneous squamous cell carcinoma tumors from immunocompetent and immunosuppressed patients revealed consistent tumor mutational signatures; however, high-immune-infiltrate tumors from immunocompetent patients had lower overall mutational burdens and lower clonal mutational burdens compared with low-infiltrate tumors from immunocompetent patients and tumors from immunosuppressed patients. The lower clonal mutational burden in high-immune-infiltrate tumors from immunocompetent patients persisted after accounting for tumor purity and growth rate. Predicted neoantigen: major histocompatibility complex (MHC) class I binding affinity decreased with increasing variant allele frequency, demonstrating restriction of mutations encoding MHC-binding neoantigens. Neoantigens with features shared with validated immunogenic neoantigens were decreased in clonal relative to subclonal cancer cell populations in high-immune-infiltrate tumors from immunocompetent patients. Thus, the immune system restricts cancer cells expressing immunogenic antigens from clonal populations in primary, treatment-naive human tumors.

    2026Immunity(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1229 篇论文

    合作机构(100)

    温纳贝戈医学中心合作论文 333
    梅奥诊所合作论文 93
    梅奥诊所佛罗里达分部合作论文 47
    明尼苏达大学合作论文 46
    梅奥诊所亚利桑那州分部合作论文 30
    乔治梅森大学合作论文 26
    林登沃德大学合作论文 24
    德克萨斯 A&M 大学合作论文 20
    伊利诺伊大学香槟分校合作论文 18
    约翰斯·霍普金斯大学合作论文 16

    机构统计